McKesson Co. (NYSE:MCK) Shares Bought by Good Life Advisors LLC

Good Life Advisors LLC increased its holdings in McKesson Co. (NYSE:MCK) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,657 shares of the company’s stock after buying an additional 202 shares during the period. Good Life Advisors LLC’s holdings in McKesson were worth $767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Koshinski Asset Management Inc. grew its position in McKesson by 1.1% in the 3rd quarter. Koshinski Asset Management Inc. now owns 2,353 shares of the company’s stock valued at $1,023,000 after buying an additional 25 shares during the last quarter. First Foundation Advisors raised its stake in McKesson by 2.7% in the 2nd quarter. First Foundation Advisors now owns 1,035 shares of the company’s stock valued at $442,000 after purchasing an additional 27 shares during the last quarter. JT Stratford LLC raised its stake in McKesson by 1.9% in the 2nd quarter. JT Stratford LLC now owns 1,483 shares of the company’s stock valued at $634,000 after purchasing an additional 28 shares during the last quarter. Avior Wealth Management LLC raised its stake in McKesson by 50.0% in the 3rd quarter. Avior Wealth Management LLC now owns 84 shares of the company’s stock valued at $37,000 after purchasing an additional 28 shares during the last quarter. Finally, PDS Planning Inc increased its stake in shares of McKesson by 3.5% during the 3rd quarter. PDS Planning Inc now owns 865 shares of the company’s stock valued at $376,000 after acquiring an additional 29 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Wells Fargo & Company started coverage on shares of McKesson in a research report on Thursday, December 14th. They set an “equal weight” rating and a $502.00 price target for the company. UBS Group lifted their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. SVB Leerink assumed coverage on McKesson in a report on Monday, February 26th. They set an “outperform” rating and a $600.00 target price on the stock. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 4th. Finally, Barclays assumed coverage on McKesson in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $537.00 price target on the stock. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and an average target price of $522.21.

Insider Buying and Selling

In other news, EVP Leann B. Smith sold 186 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at approximately $749,456. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other McKesson news, EVP Leann B. Smith sold 186 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at $749,456. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The disclosure for this sale can be found here. Insiders have sold 17,685 shares of company stock worth $8,646,498 in the last 90 days. Insiders own 0.21% of the company’s stock.

McKesson Stock Down 0.4 %

Shares of MCK traded down $2.41 during midday trading on Thursday, hitting $536.85. The company’s stock had a trading volume of 707,264 shares, compared to its average volume of 738,245. McKesson Co. has a one year low of $352.34 and a one year high of $540.00. The company’s fifty day simple moving average is $511.92 and its two-hundred day simple moving average is $474.70. The stock has a market capitalization of $70.55 billion, a price-to-earnings ratio of 24.30, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping analysts’ consensus estimates of $7.05 by $0.69. The business had revenue of $80.90 billion for the quarter, compared to analyst estimates of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. McKesson’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.90 EPS. On average, research analysts predict that McKesson Co. will post 27.61 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Investors of record on Friday, March 1st will be given a dividend of $0.62 per share. The ex-dividend date is Thursday, February 29th. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. McKesson’s dividend payout ratio is currently 11.24%.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.